33 results about "Drug taking" patented technology

The invention relates to a heart rehabilitation management method based on rehabilitation requirements. The method comprises the following steps: acquiring oxygen saturation time sequence data of a patient through wearable equipment, performing biological rhythm feature extraction on the data to construct a fluctuation model so as to capture a physiological cycle rule, and constructing a drug action factor based on a drug taking record to perform drug action calibration on original data so as to eliminate exogenous interference. Candidate time windows with consistent physiological statuses are screened through sliding window stability analysis; dynamic baseline calculation is performed on the candidate window based on long-term monitoring data to establish an individualized reference standard, when the dynamic baseline reaches the standard, the biological rhythm parameters and the drug action factors are fused to score and screen the time window, and finally, an individualized rehabilitation training scheme is generated in combination with physiological feature matching of a patient. Dynamic synergy of drug metabolism, physiological rhythm and historical baselines is achieved, the problem of physiological load imbalance caused by a static training plan is solved, and the rehabilitation efficiency is improved while the heart compensation risk is remarkably reduced.

The invention belongs to the technical field of medical management, and discloses an anesthetic medicine taking and supplementing comprehensive collaborative management system and method.The anesthetic medicine taking and supplementing comprehensive collaborative management system comprises a safe storage monitoring unit used for deploying a deformable magnetofluid sealing mechanism on an anesthetic medicine box, controlling the magnetofluid shape change through an electromagnetic signal, and sending the deformable magnetofluid sealing mechanism to the anesthetic medicine box when an unauthorized box opening behavior is monitored; the topological structure is triggered to deform to automatically lock the medicine box; the medicine taking operation unit is used for providing medicine taking path guidance through an AR interface of the medicine box and instructing the target medicine storage bin to take medicine in combination with the multi-band LED array; the medicine data insight unit is used for collecting the hemp essence medicine consumption data and the hemp essence medicine doctor advice data from the information storage terminal of the medicine storage bin, and constructing a hemp essence medicine consumption map through the hemp essence medicine consumption data; all-around safety protection, intelligent operation and accurate analysis and optimization are realized in the medicine management process, and the management efficiency, accuracy, safety and intelligent level of the hemp essence medicine are greatly improved.

The invention relates to the technical field of biological medicines, in particular to application of hsacirc0008126 in prevention and treatment of senile osteoporosis. The invention provides the circular RNA hsacirc0008126 which can be used for regulating and controlling the mesenchymal stem cell osteogenesis and adipogenic differentiation, the mechanism of the circular RNA hsacirc0008126 on the mesenchymal stem cell osteogenesis and adipogenic differentiation is different from that of the prior art, the medicine taking the circular RNA hsacirc0008126 as the target spot can be used for treating and / or preventing osteoporosis, and the circular RNA hsacirc0008126 has important application value.

The application discloses application of a reagent for detecting LRRN3 expression level in preparation of a benign prostatic hyperplasia diagnosis product. It is proved through cell function experiments and animal experiments that overexpression of the LRRN3 gene can inhibit the proliferation of prostate cells, block the cell cycle and promote cell apoptosis, thereby effectively inhibiting the prostatic hyperplasia. The discovery provides a new target and treatment strategy for the treatment of the prostatic hyperplasia, and provides a brand-new thought and method for the treatment of the prostatic hyperplasia. Based on the research results, a gene therapy drug taking the LRRN3 gene as a target can be further developed, for example, a lentivirus vector carrying the LRRN3 gene or other gene delivery systems are constructed and used for the treatment of the prostatic hyperplasia. In addition, the LRRN3 gene can be combined with other treatment methods to improve the treatment effect.

The invention discloses an equipment fault diagnosis method based on big data analysis, and relates to the technical field of drinking or drug taking detection, and the method comprises the following steps: S101, collecting the operation state information, including sensor response information and sensor resistance information, of a skin resistance sensor in a driving state rapid detection system, and after collection, sending the information to a database; and processing sensor response information and sensor resistance information when the skin resistance sensor operates. The running state of the skin resistance sensor in the driving state rapid detection system is monitored, abnormal hidden dangers of the running state of the skin resistance sensor are effectively prevented, and therefore the situation that the accuracy and reliability of the system are affected due to the fact that the skin resistance sensor generates wrong measurement results is effectively prevented; therefore, the system cannot reliably detect drunk driving and toxic driving behaviors, and cannot provide accurate alarms or trigger corresponding safety measures.

The invention provides a medical drug intelligent rental cabinet system integrating identity verification and drug use safety early warning, and relates to the technical field of water turbine blade detection, and the system comprises an identity verification module which is used for carrying out the identity information collection and validity verification of a drug taking person; the medication information matching module is used for matching the identity information of the personnel passing the identity verification with pre-stored medication prescription information; the drug use safety early warning module is used for analyzing the drug use risk based on the matching result and generating early warning information; dependence of traditional manual registration and verification is thoroughly eliminated, non-sensitization and high efficiency of identity verification and precision of medicine matching are achieved, adaptation limitation of single-mode verification is avoided, manual judgment errors are eradicated through automatic data retrieval, it is ensured that each time of medicine taking corresponds to legal personnel and compliant prescriptions, and the accuracy of medicine taking is improved. And a safety defense line for medicine access is built from the source.

The invention discloses a reversible multi-nozzle needleless injection ampoule with a turbulent flow mixing function, and belongs to the technical field of medical instruments. Due to the design of the integrally-formed nozzle base, all dynamic sealing interfaces which may fail under high pressure are eliminated, so that the pressure resistance of the ampoule is greatly improved, and the service life of the ampoule is greatly prolonged; according to intelligent switching of the injection modes, a user can switch between the deep precise injection mode and the superficial broad-spectrum coverage mode through simple rotating operation, unprecedented clinical adaptability is given to the ampoule, clear tactile / auditory feedback is achieved in the switching process, the clinical adaptability is high, and operation is convenient and fast. The multifunctional injector integrates the functions of injection mode switching, liquid medicine mixing and front-end medicine taking, and the clinical adaptability and operation convenience are improved.

The application relates to application of a medicine taking ACLY gene as an action target in preparation of a medicine for preventing and treating vascular calcification, and belongs to the technical field of biological medicine. In order to solve the problem that effective clinical means for treating vascular calcification is lacked at present, the application provides application of a medicine taking ACLY gene as an action target in preparation of a medicine for preventing and treating vascular calcification, the transcription or translation of the ACLY gene of vascular smooth muscle cells is efficiently and specifically inhibited, or the expression or activity of the ACLY protein of the vascular smooth muscle cells is efficiently and specifically reduced, the osteogenic differentiation of smooth muscle is reduced, the deposition of hydroxyapatite in the vascular media is reduced, and the progress of vascular calcification is alleviated. The medicine for preventing and treating vascular calcification is prepared on the basis of inhibition of the ACLY of vascular smooth muscle, has important clinical application potential for vascular calcification treatment, and can provide a new treatment option for patients with vascular calcification.

The invention belongs to the technical field of pharmaceutical preparations, and particularly relates to a 4-aminopyridine sustained release preparation and a preparation method thereof. The sustained release preparation comprises 4-aminopyridine, ethyl-beta cyclodextrin-calcium carbonate microspheres, a filler, an adhesive, a disintegrating agent and a lubricant. According to the sustained-release preparation, the sustained-release time can be prolonged, the medicine taking frequency is reduced, the content uniformity of the preparation is improved, meanwhile, the preparation process is improved, and stimulation to operators, environment control in a production workshop and equipment cost are reduced.

The present application relates to the field of biological medicine, in particular to the preparation of a drug or diagnostic reagent for treating Philadelphia chromosome positive leukemia by taking synaptic receptor associated protein RAPSYN or its gene as a target point. The present application specifically discloses the use of RAPSYN gene or protein as a therapeutic target in screening and / or preparation of a drug for preventing and / or treating Philadelphia chromosome positive leukemia. Philadelphia chromosome positive leukemia can be treated by negatively regulating the level and activity of RAPSYN gene or protein. The efficacy and prognosis of patients can be predicted by detecting the expression level of RAPSYN. The treatment strategy or drug taking RAPSYN gene and protein as a target point can be used as a new means of leukemia targeted therapy.

The invention provides a rapid drug taking screening method and device.The rapid drug taking screening method comprises the steps that skin spectral characteristics of a to-be-recognized user are obtained, and the skin spectral characteristics comprise at least one of skin structure characteristics, skin fingerprint characteristics and skin component characteristics; wherein the skin structure characteristics refer to the characteristics of macromolecular structures of the skin, the skin fingerprint characteristics refer to the characteristics of residual traces of foreign molecules on the skin, and the skin component characteristics refer to the characteristics of the content of inherent components on the skin; acquiring trace element characteristics of the user to be identified, wherein the trace element characteristics comprise at least one of the following characteristics: a zinc element concentration characteristic, an iron element concentration characteristic and a copper element concentration characteristic; and carrying out fusion analysis on the skin spectral features and the trace element features, and judging whether the to-be-identified user has a drug taking behavior or not based on a preset identification model. According to the embodiment of the invention, the screening accuracy and screening efficiency of the drug taking behavior can be effectively improved.

The present invention provides an anesthesia dispensing robot, which relates to the field of robot technology and includes: a drug storage area, a drug taking component, a drug review component, a drug preparation component, a display component, an input component, and a processor arranged in the robot's main structure; the drug storage area includes multiple storage partitions, each storage partition is used to store a type of anesthetic drug; the drug taking component is used to take anesthetic drugs from the drug storage area according to the drug taking instruction of the processor; the drug review component is used to weigh the amount of anesthetic drugs taken; the drug preparation component is used to mix the taken anesthetic drugs and produce anesthetic medical devices when the amount of anesthetic drugs taken is consistent with the drug taking instruction, and the processor is used to generate the drug taking instruction. According to the present invention, based on the doctor's modification and confirmation of the recommended anesthetic drug dispensing information, the recommended anesthetic drug dispensing information can be optimized to improve the accuracy of the recommendation.

The application discloses a controlled-release pharmaceutical composition and a preparation method and application thereof. The controlled-release pharmaceutical composition comprises a quick-release part and an enteric sustained-release part; the quick-release part comprises a first active ingredient, and the enteric sustained-release part comprises a second active ingredient and a sustained-release material; the first active ingredient or the second active ingredient is selected from racemic indobufen or S-indobufen or a pharmaceutically acceptable salt thereof; and the sustained-release material is selected from one or a combination of any number of hydroxypropyl methyl cellulose, hydroxypropyl cellulose, xanthan gum, sodium alginate, sodium carboxymethyl cellulose, acrylic resin, carbomer or polyethylene oxide. The composition can realize once-a-day oral administration, reduces the frequency of drug taking of a patient, and improves the drug taking compliance of the patient; the preparation process is simple, short in time, low in energy consumption, and suitable for industrial production; the influence of food on product burst release is greatly reduced, the stimulation and adverse reactions of the product on the gastrointestinal tract are reduced, and in particular, the risk of gastric hemorrhage is reduced.

The present application relates to a kind of sustained-release acyclovir tablets and its preparation process, belong to the technical field of medicine.The acyclovir tablet provided by the present application has immediate-release layer and sustained-release layer, immediate-release layer can be quickly released, rapidly increase the blood concentration in human body;Sustained-release layer has multi-stage drug release characteristics, it includes three kinds of sustained-release particles, which can effectively delay, positioning release drug, constantly supplement the blood concentration in body, maintain stable blood concentration, can effectively sustain release up to about 12h, and can maintain relatively stable blood concentration within 12 hours, reduce the frequency of drug taking, improve patient compliance, suitable for the patient with herpes simplex virus infection who needs long-term treatment.

The invention discloses a drug-resistant main protease inhibitor with stable metabolism and application thereof in preparation of antiviral drugs. In the main protease inhibitor, a group C not only can be effectively combined with an active pocket of main protease, but also the combination mainly depends on the 163rd amino acid site of the main protease; meanwhile, the group C is relatively difficult to oxidize, so that the main protease inhibitor can show basically consistent inhibitory activity to both mutant strains and wild strains, viruses do not generate drug resistance to the main protease inhibitor, and the main protease inhibitor can tolerate liver drug enzyme metabolism, has excellent drug-resistant activity and metabolic stability, and can be used for preparing the main protease inhibitor. In use, a liver drug enzyme inhibitor does not need to be used cooperatively, and reduction of self liver function decline and toxic and side effects caused by medicine taking is facilitated. In addition, the group A not only can further improve the inhibitory activity of the main protease inhibitor on the main protease, but also can enhance the anti-drug resistance activity and metabolic stability of the main protease inhibitor; and the ring B mainly plays a role in further improving the inhibitory activity of the main protease inhibitor on the main protease.

The invention discloses a crime factor correlation analysis method considering spatial heterogeneity and a zero dilatation phenomenon, which comprises the following steps of: firstly, acquiring spatio-temporal data and social population data of drug taking and drug selling cases, and obtaining initial environment factors to carry out collinearity diagnosis, screening and standardization processing to obtain built environment factors; analyzing the spatial distribution similarity of drug taking and drug selling cases; dividing analysis units, and constructing a zero-expansion negative binomial model of each analysis unit by taking the quantity of drug taking and drug selling cases as modeling objects; iterative alternative optimization is carried out on the model coefficients, and the incidence rate and the advantage ratio of explanatory variables between each built-up environment factor and the social population data are calculated; then, the optimized model is adopted to estimate regression coefficients of built environmental factors, a kernel density distribution diagram is generated, and a hotspot distribution diagram of drug taking and drug selling cases is visualized; finally, a targeted urban environment intervention strategy is provided according to a model result, and a scientific basis is provided for urban safety planning and police resource allocation and prevention.

The invention discloses a nilotinib sustained release tablet and a preparation method thereof, the nilotinib sustained release tablet comprises a bleaching assisting layer and a drug-containing sustained release layer, the bleaching assisting layer is prepared from a hydrophilic polymer with the viscosity of 2000 mpa.s-6000 mpa.s, a hydrophobic bleaching assisting agent, an adhesive and a lubricant; the drug-containing sustained-release layer is prepared from the following raw materials: an amorphous solid dispersion containing nilotinib or salt thereof, a hydrophilic polymer with the viscosity of 40 mpa.s-2000 mpa.s, a water-soluble filler, a flow aid and a lubricant. The nilotinib sustained-release tablet can effectively prolong the retention time of nilotinib in the stomach, slowly release the medicine in the stomach, improve the solubility and bioavailability of the medicine and reduce the overall dosage, so that the adverse reaction of the medicine is reduced, and meanwhile, on the basis of ensuring that the nilotinib sustained-release tablet is not affected by food effects, the nilotinib sustained-release tablet only needs to be orally taken once every day, and the curative effect of the nilotinib sustained-release tablet is greatly improved. The medicine taking compliance of a patient is improved by reducing the medicine taking times.

The invention discloses a drug-resistant main protease inhibitor with stable metabolism and application thereof in preparation of antiviral drugs. In the main protease inhibitor, a group C not only can be effectively combined with an active pocket of main protease, but also the combination mainly depends on the 163rd amino acid site of the main protease; meanwhile, the group C is relatively difficult to oxidize, so that the main protease inhibitor can show basically consistent inhibitory activity to both mutant strains and wild strains, viruses do not generate drug resistance to the main protease inhibitor, and the main protease inhibitor can tolerate liver drug enzyme metabolism, has excellent drug-resistant activity and metabolic stability, and can be used for preparing the main protease inhibitor. In use, a liver drug enzyme inhibitor does not need to be used cooperatively, and reduction of self liver function decline and toxic and side effects caused by medicine taking is facilitated. In addition, the group A not only can further improve the inhibitory activity of the main protease inhibitor on the main protease, but also can enhance the anti-drug resistance activity and metabolic stability of the main protease inhibitor; and the ring B mainly plays a role in further improving the inhibitory activity of the main protease inhibitor on the main protease.

The invention discloses an application of a Prmt5 gene and a substance for regulating expression of the Prmt5 gene in preparation of a product for treating cerebellar ataxia. The invention belongs to the technical field of biology, and particularly relates to an application of a Prmt5 gene and a substance for regulating expression of the Prmt5 gene in preparation of a product for treating cerebellar ataxia. The invention provides an application of a drug taking a Prmt5 gene as a drug action target in preparation of a drug for treating or preventing cerebellar ataxia related diseases and an application of a product for reducing formation of inhibitory synapses.

The application discloses a metabolically stable anti-drug-resistant main protease inhibitor and application thereof in preparation of antiviral drugs. In the main protease inhibitor, the group C can be effectively combined with the active pocket of the main protease, and the combination mainly depends on the 163th amino acid site of the main protease; meanwhile, the group C is difficult to be oxidized, so that the main protease inhibitor can exhibit basically consistent inhibitory activity to both mutant strains and wild strains, the virus cannot produce drug resistance to the main protease inhibitor of the application, and the main protease inhibitor has excellent anti-drug resistance activity and metabolic stability, and does not need to be used in combination with a liver enzyme inhibitor when used, which is favorable for reducing self-liver function reduction and toxic side effects caused by drug taking. In addition, the group A can further improve the inhibitory activity of the main protease inhibitor to the main protease, and can enhance the anti-drug resistance activity and metabolic stability of the main protease inhibitor; and the B ring mainly plays a role in further improving the inhibitory activity of the main protease inhibitor to the main protease.

The invention discloses a preparation method of a pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, and relates to the technical field of medicines, the pharmaceutical composition comprises a Xiaoshuitong injection as a Xiaoshuitong injection as a Xiaoshuitong injection as a Xiaoshuitong injection as a Xiaoshuitong injection as a Xiaoshuitong injection as a Xiaoshuitong injection as a Xiaoshuitong injection as a Xiaoshuitong injection as a Xiaoshuitong injection as a Xiaoshuitong injection as a Xiaoshuitong According to the preparation method of the pharmaceutical composition for treating the cardiovascular and cerebrovascular diseases, multi-target and multi-layer treatment is realized by comprehensively applying six methods of traditional Chinese medicine, and the cardiovascular and cerebrovascular functions are conditioned fundamentally; the medicine composition has a strong synergistic effect, and can be used for dissolving thrombus and dredging collaterals, repairing vascular endothelium and promoting myocardial cell regeneration; the treatment mode is safe, and western medicine operation wounds and side effects caused by long-term medicine taking are avoided; oral administration and intravenous administration are combined, so that the drug absorption and action persistence are enhanced; the traditional Chinese medicine external treatment method can be matched to further improve the curative effect and realize metabolic balance.

The invention discloses an application of SLC25A13 as a prognostic marker and a therapeutic target for predicting lung adenocarcinoma. Through large-scale and multi-queue systematic analysis, the SLC25A13 is identified as a key gene significantly related to survival of a lung adenocarcinoma patient, the defects that a traditional small sample screening or empirical target spot discovery method is poor in repeatability and high in false positive rate are overcome, and the SLC25A13 serving as a prognostic marker has higher reliability and clinical transformation potential; in addition, high expression of SLC25A13 in the invention prompts poor prognosis; prognostic risk assessment is performed based on detection of the expression level (or genetic markers related to expression) of the SLC25A13 gene or protein thereof, a relatively objective and quantitative molecular typing means is provided, and different products can be derived based on the SLC25A13. Comprising but not limited to a detection kit for prognosis prediction, a prognosis scoring model or system based on the marker, and a therapeutic drug taking SLC25A13 as a target spot.

The invention provides application of a medicine taking FZD6 as a target spot in preparation of a medicine for treating biliary atresia, and relates to the technical field of biological medicine. The research of the inventor finds that the FZD6 gene can play a causal role in BA through gene regulation and control. Enrichment analysis shows that the gene participates in various signal pathways. Through immune infiltration analysis, difference analysis and key immune cell-gene correlation analysis, it is found that FZD6 is significantly related to most BA-related immune cells. Immunohistochemical analysis proves that the FZD6 is obviously expressed in bile duct epithelial cells of a BA patient, so that the FZD6 can be used for BA diagnosis according to the expression level of the FZD6. Drug prediction and molecular docking analysis show that dexamethasone and schisandrin N have very strong binding affinity with FZD6 and are potential therapeutic drugs, and the FZD6 gene can be used as a potential drug therapeutic target of BA.

The invention relates to a cross-modal optimization method and system for chronic disease management, and relates to the field of chronic disease management, and the method comprises the steps: collecting medicine image information in response to a triggering instruction; preset medicine features are selected from the medicine image information, medicine information is obtained based on the selected medicine features, medicine taking conditions and interval time are determined according to the medicine information, and the medicine taking conditions comprise a pre-meal stage, an in-meal stage and a post-meal stage; historical medicine taking time is called based on the medicine information, target medicine taking time is determined according to the historical medicine taking time and interval time, and current time is collected; after the current time falls into the target medicine taking time, food image information is collected; broadcast content is matched based on the food image information and the medicine taking conditions, and prompting is carried out. The method has the effects of obtaining the user condition in real time and improving the data acquisition efficiency.

The invention discloses application of a reagent for detecting the expression level of LRRN3 in preparation of a benign prostatic hyperplasia diagnosis product. Cell function experiments and animal experiments prove that the overexpressed LRRN3 gene can inhibit proliferation of prostatic cells, retard the cell cycle and promote cell apoptosis, so that prostatic hyperplasia is effectively inhibited. The discovery provides a new target spot and a treatment strategy for the treatment of the prostatic hyperplasia, and provides a brand new thought and method for the treatment of the prostatic hyperplasia at the same time. Based on the research result, a gene therapy drug taking the LRRN3 gene as a target spot can be further developed, for example, a lentiviral vector carrying the LRRN3 gene or other gene delivery systems are constructed and used for treating the prostatic hyperplasia. In addition, the LRRN3 gene can be applied in combination with other treatment means, so that the treatment effect is improved.

The application belongs to the technical field of medical management, and discloses a comprehensive and collaborative management system and method for narcotic and psychotropic drugs, which comprises a safe storage monitoring unit, a drug taking operation unit and a drug data insight unit. The safe storage monitoring unit is used for deploying a deformable magnetic fluid sealing mechanism on the upper part of a narcotic and psychotropic drug box, and controlling the shape change of the magnetic fluid through an electromagnetic signal. When an unauthorized opening behavior is monitored, the topological structure is triggered to deform and automatically lock the drug box. The drug taking operation unit is used for providing a drug taking path guide through the AR interface of the drug box, and combining a multi-frequency LED array to indicate the target drug storage bin for drug taking. The drug data insight unit is used for collecting narcotic and psychotropic drug consumption data and narcotic and psychotropic drug prescription data from the information storage terminal of the drug storage bin, and constructing a narcotic and psychotropic drug consumption atlas through the narcotic and psychotropic drug consumption data. In the process of drug management, omnidirectional safety protection, intelligent operation, accurate analysis and optimization are realized, and the management efficiency, accuracy, safety and intelligent level of narcotic and psychotropic drugs are greatly improved.

The invention provides a brain-computer interface-based hypertensive drug dynamic monitoring system and a brain-computer interface-based hypertensive drug dynamic monitoring method, designs a novel hypertensive drug dynamic monitoring mechanism, and analyzes the drug effect by mixing the electroencephalogram signal, the blood pressure signal and the drug taking time to form a multi-modal signal. A series of optimization settings continue to be matched from the aspect of details, so that through multi-modal fusion, dynamic modeling, personalized optimization and clinical closed loop, the system comprehensively surpasses the prior art in the aspects of monitoring dimension, decision depth and function integration, and through collaborative analysis of nerve-blood pressure-autonomic nerve, the accuracy of the system is improved. The normal form transformation of hypertension treatment from symptomatic administration to nerve-body fluid-blood vessel coordinated regulation is promoted, and the accuracy, individuation and safety of hypertension drug monitoring are remarkably improved.

The invention discloses application of a PTPRO gene in preparation of a product for treating memory deficiency related diseases, and belongs to the technical field of biological medicines. The amino acid sequence of the PTPRO gene is shown as SEQ ID NO.1. A PTPRO gene knockout mouse is constructed, the influence of PTPRO on learning and memory functions is explored by taking the mouse as a tool, and a molecular mechanism of PTPRO playing a role is further studied, so that a drug taking the PTPRO gene as an action target can efficiently and specifically interfere with transcription or translation of the PTPRO gene on the basis of interference of the PTPRO gene, and the effect of the PTPRO gene on learning and memory functions is further studied. Further, protein expression of the PTPRO gene is promoted or enhanced, and the effect of improving memory is achieved. The invention provides a new target and a new direction for clinical treatment and prevention of learning and memory defect related diseases.

The invention relates to the technical field of medicines, and discloses a sustained-release solid chewable tablet rich in cistanche phenylethanoid glycosides and a preparation method thereof, the sustained-release solid chewable tablet comprises the following components by weight: 15-30% of a cistanche extract, 20-40% of a sustained-release matrix material, 15-35% of a chewable filler, 3-8% of a natural sweetener, 1-3% of a flavoring agent, 0.5-2% of a flow aid, 0.5-1.5% of a lubricant and 0.2-1% of a natural perfume, through a gradient baking technology, phenylethanoid glycoside active ingredients, especially echinacoside and acteoside, in cistanche deserticola are effectively reserved, meanwhile, release of components such as polysaccharide is promoted, the extraction efficiency is improved, through the scientific proportion of composite slow-release matrix materials, the tablets can slowly release the active ingredients in the body, the stable blood concentration is maintained, and the curative effect is good. The medicine action time is prolonged, the medicine taking frequency is reduced, the bitter taste of cistanche deserticola is effectively covered through scientific compatibility of a natural sweetening agent, a flavoring agent and spices, and the medicine taking compliance of a patient is improved.

The invention discloses ambroxol hydrochloride sustained-release powder and a preparation method thereof. The method comprises the following steps: S1, mixing ambroxol hydrochloride and meso-porous silicon according to a mass ratio of 1: (0.8-1.5), stirring for 5-6 hours, and drying to obtain drug-loaded meso-porous silicon; s2, mixing the drug-loaded meso-porous silicon and a sustained-release material according to a mass ratio of 1: (5.5-7), dissolving, and coating to obtain skeleton powder containing the drug-loaded meso-porous silicon; s3, embedding the skeleton powder containing the drug-loaded meso-porous silicon and a wax material according to a mass ratio of 1: (2-3) to obtain prefabricated ambroxol hydrochloride sustained-release powder; and S4, adding a flavoring agent, and mixing to obtain the ambroxol hydrochloride sustained-release powder. The ambroxol hydrochloride sustained-release powder can be slowly and stably released by combining a plurality of sustained-release technologies, so that the medicine taking frequency of children is reduced, and the medication compliance is improved.